IMUNON Announces First Patient Enrolled In Phase 1/2 Clinical Trial Of IMNN-001 In Combination With bevacizumab In Advanced Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
IMUNON, Inc. (NASDAQ:IMNN) has announced the enrollment of the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab for advanced ovarian cancer. The trial aims to enroll 50 patients with Stage III/IV advanced ovarian cancer. Initial data are expected within one year following the completion of enrollment and final data are expected approximately three years after. The company has recently announced encouraging interim data for their OVATION 2 program evaluating the benefits of IMNN-001.
October 18, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IMUNON, Inc. has begun a Phase 1/2 clinical trial for IMNN-001 in combination with bevacizumab for advanced ovarian cancer. The company has also announced encouraging interim data for their OVATION 2 program.
The initiation of the Phase 1/2 clinical trial for IMNN-001 in combination with bevacizumab for advanced ovarian cancer is a significant step for IMUNON, Inc. This, along with the encouraging interim data for their OVATION 2 program, could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100